Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.

Danielle Almeida BraggioDavid KollerFeng JinNanda SivaAbeba ZewduGonzalo LopezKara BatteLucia CasadeiMeng WelliverAnne M StroheckerDina LevRaphael E Pollock

Published in: Cancer (2019)

Our findings suggest that the response to sorafenib differs when comparing S45F-mutated DTs and T41A-mutated or wild-type DTs. Furthermore, the combination of hydroxychloroquine and sorafenib enhances the antiproliferative and proapoptotic effects in S45F-mutated DT cells, suggesting that profiling β-catenin status could guide clinical management of desmoid patients who are considering sorafenib treatment.

Keyphrases

wild type
end stage renal disease
induced apoptosis
newly diagnosed
signaling pathway
oxidative stress
epithelial mesenchymal transition
prognostic factors
cell cycle arrest
cell proliferation
patient reported outcomes
single cell
smoking cessation
pi k akt
genome wide analysis